Clinical Trials Directory

Trials / Terminated

TerminatedNCT03246620

Oral Olanzapine Versus Haloperidol or Diazepam

Oro-dispersible Olanzapine (Wafer) Versus Conventional Oral Haloperidol or Diazepam Tablets for the Management of Acute Agitation in the Accident and Emergency Department - a Multicentre Randomised Clinical Trial

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
12 (actual)
Sponsor
The University of Hong Kong · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether oral olanzapine is safer (fewer adverse events) and more effective (shorter time to sedation) than conventional haloperidol or diazepam when used in the management of acute agitation in the emergency.

Detailed description

1. Investigate oral use of sedating drugs within a predominantly Chinese population, to address this void in international literature impacting the management of acute agitation. 2. The multi-centre Randomised Clinical Trial will determine the safety and efficacy of oral olanzapine, in comparison with conventional medicines (haloperidol or diazepam) in a three-arm comparison for the sedation of acutely agitated patients in AEDs. Specifically, we aim to determine if administration of oral olanzapine (a)is more effective than sedation with oral haloperidol or oral diazepam alone; (b)is safer than sedation with comparison arms; (c)decreases the amount of subsequent redosing or alternative drugs required; (d)is more favourable than the haloperidol and diazepam arms with respect to safety, efficacy and adverse events. Investigate potential variables leading to AED attendance and/or admission requiring oral sedation. These may include patient demographic and regular medications and adherence.

Conditions

Interventions

TypeNameDescription
DRUGOlanzapine oro-dispersible 5Mg TabPatient allocated to this arm will be given 5 mg olanzapine oro-dispersible tablet and an encapsulated placebo tablet
DRUGHaloperidol 2Mg encapsulated TabPatient allocated to this arm will be given 2 mg encapsulated haloperidol tablet and an oro-dispersible placebo tablet
DRUGDiazepam 2Mg encapsulated TabPatient allocated to this arm will be given 2 mg encapsulated diazepam tablet and an oro-dispersible placebo tablet

Timeline

Start date
2017-09-01
Primary completion
2018-06-01
Completion
2018-06-01
First posted
2017-08-11
Last updated
2022-11-04

Locations

1 site across 1 country: Hong Kong

Source: ClinicalTrials.gov record NCT03246620. Inclusion in this directory is not an endorsement.